1. Market Research
  2. > Life Sciences Market Trends
COVID-19 Therapy and Vaccine Drug Pipeline and Clinical Trials Report- September 2020 Update

COVID-19 Therapy and Vaccine Drug Pipeline and Clinical Trials Report- September 2020 Update

  • September 2020
  • 2300 pages
  • ID: 5968526
  • Format: PDF
  • VPAResearch

Summary

Table of Contents

COVID-19 Pipeline Analysis
The September 2020 updated COVID-19 report identifies 440 companies investing in therapy and vaccination products. Around 24 companies have advanced their products into Phase 3 and around 15 companies are in Phase 2/3. Pipeline candidates of 114 companies are in phase 1 or phase 2. 23 companies are in IND/CTA filed phase.
The early development COVID-19 product pipeline is much stronger with 135 companies investing their R&D resources in preclinical COVID, 127 companies developing Research phase products.
The research report is a comprehensive market research on COVID-19 pipeline products detailing the companies, drug and vaccine candidates, their current status, historical developments and other progress.
The COVID pandemic is resulting in significant health and economic impact on individuals and businesses across the world. Accordingly, companies like Inovio, Pfizer, Johnson and Johnson, Novavax are forming joint ventures, GlaxoSmithKline is extending access to vaccine adjuvant platform, and Sanofi is sharing its expertise with BARDA among others.
Following the release of SARS-CoV-2 genome sequence, majority of companies ranging from severe acute respiratory syndrome (SARS) and Middle East Respiratory Syndrome (MERS) are focusing on vaccine candidates for COVID-19.

COVID-19 Clinical Trials Analysis
The section presents a comprehensive 1800 page analysis on all clinical trials across 96 countries worldwide. The report provides phase wise analysis, region wise clinical trials, trials sponsored directly by companies and through universities, drugs under development, trials in emerging economies and developed countries, and subjects enrolled across phases, geographies, companies, trial status, trial types and countries.
During the 2019 to August 2020 observation period, 1194 COVID-19 trials have been initated and an additional 503 clinical trials are planned to commence. Of the total 1697 trials studied in the research, 726 trials are in Phase 2, 549 trials are in Phase 3, 220 trials in Phase 0 and Phase 1, and 183 trials in Phase 4. In terms of enrollment, 62% of subjects are recruited/planned for Phase 3.
Around 84% of trials are recruiting or planning to recruit subjects for their pipeline product development. Over 21% of trials are directly sponsored by pharmaceutical companies with the remaining 79% being sponsored indirectly by companies or sponsored by institutions.
Among countries, the US stood the largest market worldwide, accounting for 441 clinical trials. Among economy types, advanced and emerging economies share an almost equal volume of trials with the former accounting for 53% of trial count.
Overall, during the period under consideration, new clinical trial count has been steadily increasing. Further, with robust market outlook, the number of clinical trials and enrolment is also expected to increase steadily through 2022.

Potential Drugs under analysis in COVID-19 clinical trials
Abatacept, Abidole , Abivertinib, ABX464, Acalabrutinib, ACE inhibitor, Acetaminophen, acetylsalicylic acid, adalimumab, Aescinate , AG0301, Alafenamide , Alendronic Acid , Alkaline phosphatase, Almitrine, alpha-Interferon, Alteplase, Ambrisentan, Amiodarone, Amlodipine besilate, Ampion, AMY-101, ANAKINRA, ANG-3777, Angiotensin 1-7, Angiotensin receptor blocker, Anluohuaxian, AOIM - Z , Apilimod Dimesylate , Apixaban, APL-9, apocynin, Apremilast, Aprepitant, APROTININ, Arbidol Hydrochloride, ARCT-021, Argatroban, ARGX-117, ArtemiC, Artemisinin, ascorbic acid, Aspirin, Astegolimab, ASUNERCEPT, AT-001, AT-527, Atazanavir , ATI-450, Atorvastatin, Atovaquone, ATYR1923, avdoralimab, Avigan, Aviptadil, AVM0703, AZD1656, AZD7442, AZD7986, Azithromycin, Azivudine, azoximer bromide, Babaodan, Bactek-R, Baidu Duan Fang, Baloxavir Marboxil, Bardoxolone methyl, BARICITINIB, BAT2020, BBV152, BDB-001 , bemcentinib, Bemiparin, Berberine, betafron, Bevacizumab, Bicalutamide, BIO 300, BIO101, Biomodulina T, bismuth potassium citrate, Bivalirudin , BLD-2660, BMS-986253, BNT162, Botulinum Neurotoxin, Bovine Lipid Extract Surfactant, Brensocatib, Brequinar, BRII-196, BRII-198, bromelain, Bromhexine, Bucillamine, Budesonide, Calcifediol, Camostate mesylate, Camrelizumab, Canakinumab , Candesartan, Carrimycin, Ceftriaxone, Celebrex , Cenicriviroc, CERC-002, chloroquine , Chloroquine Diphosphate, Chloroquine phosphate, Chlorpromazine, Cholecalciferol, Ciclesonide, CICLOSPORIN, CIGB 2020 vaccine, CIGB 300 , CIGB-258 Peptide , CK0802, Clarithromycin, clavulanate, Clazakizumab, CLEVIRA , Clevudine, Clindamycin, Clofazimine, Clopidogrel, Cobicistat, Colchicine, corticosteroid , Cospherunate, CPI-006, Crizanlizumab, Crocetin, CSA0001, cyclosporin, CYNK-001, CYP-001, CYT107, Daclatasvir, Dalteparin, Danoprevir, Dapagliflozin, DARUNAVIR, DAS181, Decitabine, Deferiprone, Deferoxamine, Defibrotide, Degarelix, Dendrobium candidum, Desferal, Desidustat, Dexamethasone, dextrose, DFV890, diltiazem, Diphenhydramine, Dipyridamole, Disulfiram, Dociparastat sodium, Dolquine, Dornase Alfa, Doxycycline, DUR-928, Dutasteride, Duvelisib, ebastine, Ebselen, EC-18, Eculizumab, edaravone, EDP1815, EIDD-2801, Emapalumab, Emtricitabine, Enoxaparin, Enzalutamide, EPARINA, Estradiol, Etoposide, F-652, Famotidine, Favipiravir, Febuxostat, Fingolimod, Fisetin, Fluoxetine, Fluvoxamine, Folic Acid, Fondapariniux, Formoterol, fostamatinib disodium hexahydrate, FT516, Galidesivir, Garadacimab, Gemtuzumab ozogamicin, Gimsilumab, GLS-1200, GS-5734, GX-19, HA330, Heberon Alfa R , Heparin, Hesperidin, hydrocortisone, Hyperbaric Oxygen, Ibrutinib, Ibudilast, Ibuprofen, Icatibant, Icosapent ethyl, IFX-1, Iloprost , ILT101, Imatinib, IMM-101, IMU-838, Indomethacin, Infliximab, INM005, INO-4800, Interferon Alfa, interferon beta, Isoflurane, Isoprinosine, Isotretinoin , itolizumab, ITRACONAZOLE, Ivermectin, Ixekizumab , Jakotinib hydrochloride, JS016, KB109 , KBP-201 , Ketamine, Khorasan asafoetida, kolimycin, Lactoferrin, lanadelumab, Lariam, L-ascorbic acid, LAU-7b, LB1148, L-cysteine, Ledipasvir, Leflunomide, Lenalidomide, Lenzilumab, Leronlimab, Levamisole, Levilimab, Lianhua Qingwen , Linagliptin, Lipoic acid, Losartan , Losmapimod , Lucinactant, LY3127804, LY3819253, M5049, Maraviroc, MAS825, Masitinib mesilate, mavrilimumab, MEDI3506, MEFLOQUINE, Melatonin, Melphalan, Meplazumab , Merimepodib, metenkefalin, Metformin, Methotrexate, methylprednisolone , metoprolol tartrate, metronidazole, midazolam, minocycline, MK-5475, Moxibustion , mRNA-1273, MRx-4DP0004, Mucodentol, MultiStem, MVC-COV1901, Mycobacterium w, N acetylcysteine, N-803, NA-831, N-Acetyl cysteine, NADROPARIN, Nafamostat Mesylate, Naltrexone, Namilumab, nangibotide, nanocurcumin, Naproxen, NasoVAX, Nebulised heparin, Nelfinavir, Niacin-Tannin, Niclosamide, Nifedipine, Nintedanib , Nitazoxanide , Nivolumab , Noscapine, Novaferon, NP-120 , NT-I7, OctaplasLG, olchicine/Statins, Olokizumab, Omegaven, Omeprazole, OP-101, Opaganib, Oseltamivir, Otilimab, Ozanimod, Pamrevlumab, PB1046, Pegylated interferon lambda, Pembrolizumab, Pentaglobin, Pentoxifylline, Pertuzumab, PH94B, PHR160, Piclidenoson, Pioglitazone, Pirfenidone, Plitidepsin, PLX-PAD, Povidone-iodine, Prasugrel Hydrochloride, Prazosin, Prednisolone, Previfenon, Probiorinse, Progesterone, Prolongin, Propranolol Hydrochloride, Proxalutamide, PSC-04, PTC299, PUL-042, Pulmozyme, Pyramax, Pyridostigmine, qingfei detoxification, raltagravir, Ramelteon, Ramipril, Rapamycin, Ravulizumab, Razuprotafib, RBT-9, rednisolone, Reginmune , REGN10933, REGN10987, Remdesivir, Remestemcel-L, RESP301, resveratrol, Ribavirin, RITONAVIR, Ritonavir , Rivaroxaban, RPH-104, RTB101, Ruxolitinib, SAB-185, SAR443122, SARILUMAB, SBI-101, SCB-2019, SCTA01, Secukinumab, Secuquinumab, selenium, Selinexor, Septimeb, Sevoflurane, Shenfu, Sildenafil, Silibinin, Siltuximab, Silymarin, simvastatin, Sirolimus, Sirukumab, Sitagliptin, SivoMixx , Sofosbuvir, Spironolactone, STI-1499, sulfamethoxazole, sulfate, Sulodexide, TAK-671, Tamiflu, Tamoxifen, Tanacetum parthenium, Tannin, Tanreqing, TD-0903, TD139, Teicoplanin IV, Telmisartan, Tenecteplase, Tenofovir, Teprenone, Tetrandrine, thalidomide, Thymalfasin, Thymoquinone, Thymosin Alpha 1 , Tinzaparin , Tirofiban, TJ003234, TL-895, TMV-083, Tociliuzumab, Tradipitant, Tramadol, Tranexamic acid, Tranilast, Trastuzumab, Triazavirin, Tricholoma, tridecactide, Trifluoperazine, TRV027, TXA127, TY027, Ulinastatin, Umnifenovir, V591, vadadustat, VAFIDEMSTAT, Valsartan (Diovan), Vancomycin, Vazegepant , Velpatasvir, Veru-111, Videsil, Vidofludimus calcium, Virazole, VPM1002, XAV-19, XC221, Xinguan-1 , Xinguan-2 , Xiyanping , XPro1595, Xuebijing , yohimbine, Zanubrutinib, Zilucoplan, ZingiVir H, ?-Globulin

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers

Drug-Coated Balloons Market - Global Outlook and Forecast 2020-2025

  • $ 3500 - $ 2800 - Get 20% off now!
  • November 2020
  • 263 pages

In-depth Analysis and Data-driven Insights on the Impact of COVID-19 Included in this Global Drug-Coated Balloons Market Report The drug-coated balloons market by revenue is expected to grow at a CAGR ...

  • World
  • Hospital
  • Therapy
  • Industry analysis
  • Elderly Population
  • Drug Approval

Global Mold Inhibitors Industry $ 4950 September 2020


ref:plp2020

Reportlinker.com © Copyright 2020. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on